Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook.
Humans
Alarmins
Biological Products
/ therapeutic use
Immunity, Innate
Adrenergic beta-2 Receptor Agonists
/ therapeutic use
Administration, Inhalation
Lymphocytes
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Inflammation
/ drug therapy
Adrenal Cortex Hormones
/ therapeutic use
Bronchodilator Agents
/ therapeutic use
COPD
alarmins
biologics
eosinophils
type 2 inflammation
Journal
American journal of respiratory and critical care medicine
ISSN: 1535-4970
Titre abrégé: Am J Respir Crit Care Med
Pays: United States
ID NLM: 9421642
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
medline:
16
8
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with a significant impact on patients' lives, including morbidity and mortality, and significant healthcare costs. Current pharmacologic strategies, including first- and second-line therapies such as long-acting β
Identifiants
pubmed: 37348121
doi: 10.1164/rccm.202303-0455CI
doi:
Substances chimiques
Alarmins
0
Biological Products
0
Adrenergic beta-2 Receptor Agonists
0
Adrenal Cortex Hormones
0
Bronchodilator Agents
0
Types de publication
Video-Audio Media
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-405Subventions
Organisme : Department of Health
Pays : United Kingdom